Clinical Trial Update: Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update on the efficacy and safety of anlotinib as maintenance therapy after first-line chemotherapy in small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of the Lung
• Lung Neoplasm
• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: First Hospital of Shijiazhuang City | Conditions: Carcinoma, Lung Neoplasm | Phase 2 | Status: UNKNOWN